Introduction
Drug-eluting stents (DES) are increasingly used in vascular intervention to effectively restore blood flow in stenotic arteries. DES market development requires inexpensive high throughput coating process technology. At the same time, coating quality requirements for DES are being elevated by regulatory authorities, and new DES concepts are entering the market. Among these novel DES concepts fully absorbable polymeric DES platforms are emerging, as well as dual drug DES based on permanent metallic stent platforms. Both approaches require sophisticated coating technologies to account for the nature of the stent platform, the intended coating design, and the coating compounds. In this study, the complementary potentials of a spray-coating technology and a fluidized bed coating technology were assessed.
Methods
Absorbable polymer stents (CORMERIC, University of Rostock, 5.0 x 20 mm) based on a poly(L-lactide) (PLLA) blend and permanent cobalt chromium (L605) stents (ProKinetic, BIOTRONIK, 3.0 x 15 mm), Fig. 1 , were coated with either pure PLLA, PLLA incorporated with the immunosuppressant sirolimus (SIR) in a ratio of 85/15 % w/w, or PLLA incorporated with fluorescein sodium (50 % w), curcumin (23 % w), and quinine (30 % w). Chloroform was used as solvent for spray-coating, while dichloromethane/methanol was used for fluidized bed coating. For spray-coating a self-developed atomization technology according to [1] was applied. The absorbable polymeric stent platform was coated in a single step process (15 -30 mm working distance, 0.2 -0.4 bar gas and liquid pressure) to apply an even coating over the entire stent surface. The permanent metallic stent platform was spray-coated to achieve a conversely asymmetric abluminal/luminal coating sandwich, which is intended as a carrier for dual drug-systems to selectively address local processes at the luminal and abluminal stent surface, respectively. For fluidized bed coating a process adapted from [2] was applied, using a bottom-spray setup in a Mini-Glatt fluidized bed apparatus equipped with a Micro-Kit product container, a Wurster bottom plate (Glatt GmbH, Germany) and a spray nozzle with an orifice diameter of 0.3 mm. The coating process was performed on the permanent metallic stent platform at 0.3 bar inlet gas pressure and 1.1 bar liquid pressure. In contrast to spray-coating as a commonly single stent coating technology, fluidized bed coating is a dedicated batch coating technology. Using the currently employed micro-process container, about 400 -1200 stents can be coated per process cycle. An overview of variable parameters of both processes is given in Tab. 1. The resulting polymer/drug-coated stent samples were assessed with scanning electron microscopy (SEM) regarding surface morphology. Samples with the applied sandwich coating were embedded in epoxy resin and cross-sectioned for the evaluation of local coating thickness distribution via SEM. Coating homogeneity of samples coated with the fluorescent model substances was also studied by fluorescence microscopy (FLM).
Results
Suitable process parameters could be identified for spraycoating and fluidized bed coating to achieve the desired coating characteristics. Distinct differences were observed in process yield, Tab. 2. 
Discussion
Dedicated reproducible spray-coating and fluidized bed coating processes were established and evaluated for PLLAbased DES coatings on absorbable and permanent stent platforms. Favorable surface morphology and high coating uniformity could be shown. While particular advantages of spray-coating can be seen in specialty applications, such as sandwich coatings, the fluidized bed process shows tremendous throughput, is highly scalable and holds great industrial potential, particularly for classic DES coating designs. 
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